Abstract
Sulfamethazine acetylation phenotype was determined in 49 patients with cancer of the colon or rectum, 41 old, and 45 young control subjects. Metabolic clearance of sulfamethazine, plasma ratio of N-acetylsulfamethazine:N-acetylsulfamethazine plus sulfamethazine and urinary ratio of N-acetylsulfamethazine:N-acetylsulfamethazine plus sulfamethazine were used to classify subjects into slow and fast acetylation phenotypes. All three measures gave similar results. The proportions of slow and fast acetylators were similar in both control groups and there were significantly more fast acetylators in the cancer group than in the control groups (ϰ2 = 5.0–8.5; P < 0.05). The data suggest that there may be an association between acetylation phenotype and colorectal carcinoma.
Footnotes
-
↵1 This work was supported by a grant from the Cancer Foundation of Western Australia.
-
↵2 To whom requests for reprints should be addressed, at Department of Pharmacology, University of Western Australia, Nedlands, Western Australia 6009.
-
↵3 Recipient of a John O'Hara Research Fellowship from the Pharmaceutical Society of Western Australia.
- Received July 8, 1986.
- Revision received November 14, 1986.
- Accepted November 17, 1986.
- ©1987 American Association for Cancer Research.
Volume 47, Issue 5
